ID   K562/ZD1694.C
AC   CVCL_S663
SY   K562/ZD1694 x C
DR   Wikidata; Q54899419
RX   PubMed=8576277;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; ZD1694).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 29-06-23; Version: 17
//
RX   PubMed=8576277; DOI=10.1007/BF01226268;
RA   Takemura Y., Gibson W., Kimbell R., Kobayashi H., Miyachi H.,
RA   Jackman A.L.;
RT   "Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells
RT   sensitive, or made resistant, to this drug.";
RL   J. Cancer Res. Clin. Oncol. 122:109-117(1996).
//